Dolaf- An International Multicenter Phase 2 Trial Of Durvalumab (Medi4736) Plus Olaparib Plus Fulvestrant In Metastatic Or Locally Advanced Er-Positive, Her2-Negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity To Olaparib (Ucbg308)
CANCER RESEARCH(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要